235 Studies Now Enrolling
Menu
Search
Medical Condition
Displaying 1 - 14 of 14
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
This study is testing whether giving an investigational drug called C1 esterase inhibitor (C1INH) directly into the donor kidney before transplant can improve kidney function one year after surgery. At the time of the deceased donor kidney transplant, participants will be randomly assigned to…
Condition: Transplant / Kidney Transplant
Investigator: Joshua Weiner, MD
Status: Currently Recruiting
The goal of this clinical trial is to learn if an investigational medication called siplizumab can prevent rejection of a kidney transplant patients with end stage kidney disease. The study will compare two different doses of siplizumab to a medication that is standardly used post kidney transplant…
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
This study is testing whether a new investigational medicine called frexalimab can safely and effectively prevent kidney transplant rejection compared to tacrolimus, a standard medication currently used after transplant. Participants will be randomly assigned to receive either frexalimab (given…
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
The main goal of this clinical trial is to determine if an investigational medication called VEL101 is safe, well tolerated, and effective in people receiving a new kidney transplant. Participants will be randomly assigned to 2 different doses of VEL-101 or to tacrolimus, which is standardly used post-…
Condition: Transplant / Kidney Transplant
Investigator: Joshua Weiner, MD
Status: Closed
This is a 60-month adaptive to evaluate three siplizumab-based treatment regimens in kidney transplant recipients. The purpose of this research study is to see if the anti-rejection medications that patients normally take after transplant can be reduced or stopped completely by using several…
Condition: Transplant / Kidney Transplant
Investigator: Elizabeth Verna, MD
Status: Closed
Kidney transplant extends life, improves quality of life, and reduces healthcare costs. Unfortunately, there are not enough donated kidneys, so many people who need a transplant spend years on the waiting list. Kidneys from organ donors who have hepatitis C virus (HCV) are often thrown away, but…
Condition: Transplant / Kidney Transplant
Investigator: Marcus Pereira, MD, MPH
Status: Closed
This purpose of this study is to understand the interaction between two different medications, tacrolimus and Paxlovid (nirmatrelvir/ritonavir), in patients who have had a kidney transplant and are being treated by their doctor for COVID-19 infection. Tacrolimus is an oral medication that is used standardly in kidney…
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Closed
The purpose of this study is to determine if an investigational drug called tegoprubart (also known as AT1501) is safe and effective in preventing rejection in patients who are undergoing a kidney transplant for the first time. Participants will be randomly assigned to tegoprubart or standard treatment with tacrolimusat the…
Condition: Transplant / Kidney Transplant
Investigator: Mark Hardy, MD
Status: Closed
Subjects who undergo a kidney transplant require long term use of anti-rejection (immunosuppressive)drugs to prevent their body's immune system from attacking and damaging the newly transplanted kidney (rejection).The purpose of this study is to evaluate benefits and risks of two combinations(…
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Closed
The purpose of this research study is to see if an investigational drug, BB3, is safe and effective forincreasing the amount of urine that a transplanted kidney will produce. An investigational drugis one that is not approved by the United States Food and Drug Administration (FDA). BB3 is agrowth factor-like drug, which means…
Condition: Transplant / Kidney Transplant
Investigator: Thomas Nickolas, MD, MS
Status: Closed
Kidney transplant patients are at a higher risk for bone fractures compared to the general population. We are doing a clinical trial to examine the effects of 12-months of treatment with denosumab, a monoclonal antibody against RANKL, on bone density and strength as determined by bone imaging and by non-invasive measures of…
Condition: Liver Disease / Cirrhosis of the Liver
Investigator: Julia Wattacheril, MD, MPH
Status: Currently Recruiting
The purpose of this research study is to determine how well BI3802876 is tolerated in people living with cirrhosis due to a liver condition called metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH). The study medication, BI3802876, is investigational, meaning it has not yet been approved by the United States Food and Drug…
Condition: Liver Disease / Cirrhosis of the Liver
Investigator: Elizabeth Verna, MD
Status: Currently Recruiting
The purpose of this research study is to determine whether rosuvastatin is safe and can help people living with cirrhosis lead longer, healthier lives. The study drug, rosuvastatin, is investigational, meaning it has not yet been approved for market use for this disease condition by the United States Food and Drug Administration (FDA). Participants will…
Condition: Liver Disease / Cirrhosis of the Liver
Investigator: Elizabeth Verna, MD
Status: Closed
LCN Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months for a total of 3 years. Some of the visit…